Soft Tissue Graft for Repair of Pelvic Organ Prolapse
Overview
The purpose of this Study is to collect information about the performance of the Surgisis® Soft Tissue Graft ("Study Product") for the repair of pelvic organ prolapse in women.
Full Title of Study: “A Post-Market Study of Surgisis® Soft Tissue Graft for Repair of Pelvic Organ Prolapse”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: April 17, 2017
Interventions
- Device: Surgisis® Soft Tissue Graft
- Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
Arms, Groups and Cohorts
- Experimental: Surgisis® Soft Tissue Graft
Clinical Trial Outcome Measures
Primary Measures
- Rate of recurrence of pelvic organ prolapse
- Time Frame: 12 months
Participating in This Clinical Trial
Inclusion Criteria
- Patients in need of transvaginal surgical repair of primary (i.e., de novo) pelvic organ prolapse. – POPQ = stage 2 or 3 in the vaginal compartment with the leading edge of prolapse (i.e., more severe prolapse) – At least one symptom associated with prolapse (e.g., any of the following including but not limited to vaginal bulge, vaginal pain/discomfort, voiding dysfunction, manual reduction (digitation) needed for defecation, fecal incontinence, dyspareunia) Exclusion Criteria:
- Age < 18 years – BMI > 40 – Not medically fit for transvaginal surgery under general or spinal anesthesia – Active UTI at the time of the index procedure as determined by urine culture – Vaginal atrophy (Note: Patient may be included after vaginal atrophy has been effectively treated.) – Prior placement of synthetic mesh or biologic graft for pelvic organ prolapse – A history of cervical, ovarian, uterine, endometrial, vaginal, vulval, colon, rectal or bladder cancer – Currently planned obliterative surgical repair for pelvic organ prolapse – Systemic infection at the time of surgery – Requires chronic immunosuppressive therapy, including steroids or cytotoxic agents – Pregnant, breastfeeding or planning pregnancy during the study period – Previous diagnosis of collagen disorder (i.e., Marfan's, Ehlers-Danlos) – Physical allergies or cultural objections to the receipt of porcine products – Life expectancy of less than 12 months – Ongoing participation in an investigational device or drug trial – Currently undergoing evaluation or treatment for chronic pelvic pain (e.g., pain as a result of interstitial cystitis, endometriosis, vulvodynia, pelvic congestion syndrome) – Active vaginal infection at the time of the index procedure – History of pelvic inflammatory disease
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Cook Group Incorporated
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.